Grantland E. Bryce

Corporate Secretary at Regulus Therapeutics, Inc.

Grantland E. Bryce

Grantland E. Bryce

Corporate Secretary at Regulus Therapeutics, Inc.

Biography

Grantland E. Bryce is former Vice President-Legal & General Counsel at Ionis Pharmaceuticals, Inc.

Overview
Career Highlights

Ionis Pharmaceuticals, Inc.

RelSci Relationships

182

Relationships
RelSci Relationships are individuals Grantland E. Bryce likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at SENTÉ, Inc. (California)

Relationship likelihood: Average

Associate Member, Director, Systems Immunology at Benaroya Research Institute at Virginia Mason

Relationship likelihood: Average

Professional at Juniper Point, Inc.

Relationship likelihood: Average

Professional at Nitto Denko Technical Corp.

Relationship likelihood: Average

Vice President, Pharmaceutical Development at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Senior Vice President, Human Capital at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Secretary & Vice President-Legal Affairs at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Former Senior Research Investigator & Oncology Therapeutic Area Head, Oncology Research Unit at Pfizer, Inc.

Relationship likelihood: Average

Associate Director, CMC Analytical Development at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Former Chief Medical Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Paths to Grantland E. Bryce
Potential Connections via
Relationship Science
You
Grantland E. Bryce
Corporate Secretary at Regulus Therapeutics, Inc.
Career History
Corporate Secretary
Tenure Unconfirmed

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Vice President-Legal & General Counsel
Prior

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Transactions
Details Hidden

Regulus Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Regulus Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Regulus Therapeutics, Inc. raised money in a private placement transaction

Other Affiliations

Grantland E. Bryce is affiliated with Regulus Therapeutics, Inc., Ionis Pharmaceuticals, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Grantland E. Bryce. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Grantland E. Bryce's profile does not indicate a business or promotional relationship of any kind between RelSci and Grantland E. Bryce.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/grantland-e-bryce-4004906
  • https://relationshipscience.com/person/grantland-e-bryce-4004906